Imegli 500mg Tablet

Uses of Imegli 500mg Tablet

• Type II Diabetes Mellitus

How does Imegli 500mg Tablet work?

Imegli 500mg Tablet contains Imeglimin, which belongs to the amino triazines class of antidiabetic medicine. It works in two ways: 1) increased glucose-stimulated insulin secretion (GSIS) and cell mass preservation; 2) improved insulin action, including the potential for reduction of hepatic glucose output and improvement in insulin signaling in both the liver and skeletal muscle.

Side Effects of Imegli 500mg Tablet

• Headache
• Nausea
• Stomach upset
• Hypoglycemia
• Abdominal pain
• Constipation

Quick Suggestions:

• Hypoglycemia (low blood sugar level) may occur when taken along with other antidiabetic medicines, alcohol, or by delaying/skipping a meal. Check your blood sugar levels and have a snack/sugar source for immediate relief.
• If you get unusually thirsty, pass urine more frequently, and feel tired, let your doctor know. These are signs that there is too much sugar in your blood and your dose may need adjusting.
• Monitor your blood sugar regularly while taking this medicine.
• Inform your doctor immediately if you experience rapid or deep breathing, muscle pain, fatigue, and drowsiness.
• Lifestyle changes like low sugar diet, exercising, losing weight, not smoking, and cutting down on the amount of alcohol you normally drink may help this medication work better.

Type II Diabetes Mellitus:

• Insulin Resistance: Type II Diabetes is characterized by insulin resistance, which means that the body's cells do not respond effectively to insulin. Insulin is a hormone that regulates blood sugar (glucose) by allowing glucose to enter cells and be used for energy. When cells become resistant to insulin, blood sugar levels rise, leading to hyperglycemia (high blood sugar).
• Age and Risk Factors: While Type II Diabetes was traditionally referred to as adult-onset diabetes due to its higher prevalence in middle-aged and older adults, it is increasingly affecting younger individuals, including children and adolescents. This shift is partly attributed to lifestyle factors such as poor diet, sedentary behavior, and rising obesity rates.
• Symptoms: The symptoms you mentioned, including increased thirst (polydipsia), frequent urination (polyuria), slow wound healing, increased hunger (polyphagia), fatigue, weight gain or unintended weight loss, and blurred vision, are classic signs of diabetes. These symptoms often develop gradually and may go unnoticed for some time.
• Complications: Type II Diabetes can lead to a range of complications affecting various organs and systems in the body. Neuropathy can cause tingling, numbness, or pain in the extremities. Nephropathy can lead to kidney damage, while retinopathy affects the eyes and can result in vision impairment or blindness. Diabetes is also a significant risk factor for cardiovascular diseases, including heart attacks and strokes.
• Prevention and Management: Lifestyle modifications, including a balanced diet, regular physical activity, and weight management, play a crucial role in preventing and managing Type II Diabetes. Medications, including oral antidiabetic drugs and insulin, are often prescribed to control blood sugar levels. Regular monitoring of blood sugar, blood pressure, and cholesterol levels is essential for diabetes management.
• Holistic Care: Managing Type II Diabetes involves a comprehensive approach, addressing not only blood sugar control but also the management of associated conditions and risk factors. Regular check-ups with healthcare providers, diabetes educators, and dietitians, along with a support system, can improve overall well-being.

Pharmacology

• Amplification of Glucose-Stimulated Insulin Secretion (GSIS): Imeglimin enhances the ability of beta cells in the pancreas to release insulin in response to increased blood glucose levels. This is a crucial aspect of diabetes management because T2D is characterized by reduced insulin secretion and impaired response to glucose.
• Preservation of Beta-Cell Mass: Imeglimin helps preserve the population of beta cells in the pancreas. Beta cells are responsible for producing insulin. In T2D, there is often a gradual loss of beta-cell mass and function. By preserving these cells, Imeglimin supports the body's ability to produce insulin.
• Enhanced Insulin Action: Imeglimin also improves the way insulin works in the body. This includes enhancing the effectiveness of insulin in reducing glucose production by the liver (hepatic glucose output) and improving insulin signaling in both the liver and skeletal muscle. These actions help reduce blood glucose levels.
• Mitochondrial Function: One of the unique aspects of Imeglimin's mechanism is its impact on mitochondrial function. It corrects mitochondrial dysfunction, which is increasingly recognized as a factor in T2D pathogenesis. By improving mitochondrial function, Imeglimin helps reduce oxidative stress (excessive reactive oxygen species) and prevents mitochondrial permeability transition pore opening, which can lead to cell damage or death.
• Glucose-Stimulated ATP Generation: Imeglimin enhances the generation of ATP (adenosine triphosphate), a key source of cellular energy, in response to glucose stimulation. This is essential for beta-cell function and insulin secretion.
• NAD+ Metabolism: Imeglimin induces the synthesis of nicotinamide adenine dinucleotide (NAD+) through the "salvage pathway." NAD+ is a co-factor involved in various cellular processes, including energy metabolism and regulation of calcium mobilization. This synthesis contributes to the increased GSIS.
• Beta-Cell Mass Preservation: Imeglimin has been shown to preserve beta-cell mass in animal models of T2D. This is important for maintaining long-term insulin production capacity.

Imeglimin's multifaceted approach, addressing both insulin secretion and insulin action, as well as mitochondrial function and beta-cell preservation, makes it a promising candidate for the management of T2D. Its unique mechanism sets it apart from other diabetes medications, offering the potential for improved glycemic control and reduced risk of diabetes-related complications.

It's worth noting that research and clinical trials continue to explore Imeglimin's efficacy and safety in treating T2D, and its availability may vary by region and regulatory approvals. Patients with T2D should always consult with their healthcare providers to determine the most suitable treatment plan for their specific condition.

Dosage & Administration of Imegli 500mg Tablet

The typical dosing information for an Imegli 500mg Tablet is as follows:

Adult Dose:

• The usual adult dosage is 1000 mg of Imegli 500mg Tablet administered orally twice daily. It should be taken in the morning and evening.

Child Dose:

• Imegli 500mg Tablet is not recommended for use in children. The safety and effectiveness of this medication in pediatric patients have not been established.

Renal Dose:

• Imegli 500mg Tablet is considered safe for use in patients with kidney disease, and no dose adjustment is recommended based on renal function. However, it's essential to follow the prescribed dose and any specific recommendations provided by your doctor.

Administration Instructions:

• Take Imegli 500mg Tablet as directed by your healthcare provider.
• Swallow the tablet whole; do not chew, crush, or break it.
• Imegli 500mg Tablet should be taken with food.

Interaction

Drug-Drug Interactions:

• Antidepressant (Bupropion): There may be an interaction between Imegli 500mg Tablet and bupropion, an antidepressant. It's important for healthcare providers to monitor patients taking both medications for potential interactions or side effects.
• Glaucoma Medications: Imegli 500mg Tablet may interact with drugs used to treat glaucoma. Patients using both medications should be monitored for any potential interactions.
• Antibiotics (Cephalexin, Ciprofloxacin): Interactions with antibiotics like cephalexin and ciprofloxacin should be considered, and appropriate precautions may be necessary when using these drugs concurrently with Imegli 500mg Tablet.
• Anti-Acidity Drugs (Cimetidine): Cimetidine, used to treat acid-related conditions, may interact with Imegli 500mg Tablet. Monitoring and dose adjustments may be needed if both drugs are prescribed together.
• Heart Condition Medications (Digoxin): Imegli 500mg Tablet may interact with digoxin, a medication used for heart-related conditions. Healthcare providers should monitor patients taking both medications for potential interactions.
• Anti-Epileptic Drugs (Topiramate, Lamotrigine): Imegli 500mg Tablet interactions with anti-epileptic drugs like topiramate and lamotrigine should be considered. Patients on these medications may require close monitoring.
• Heart-Related Chest Medicine (Ranolazine): There may be an interaction between Imegli 500mg Tablet and ranolazine, a medication used for heart-related chest conditions. Monitoring and potential dose adjustments may be necessary.

Drug-Food Interactions:

• Excessive alcohol consumption may increase the risk of a life-threatening condition known as lactic acidosis when taking an Imegli 500mg Tablet. Patients are advised to avoid excessive alcohol intake while using this medication.

Drug-Disease Interactions:

• Individuals with kidney or liver disease or heart problems should inform their doctor before taking Imegli 500mg Tablet. Healthcare providers may need to consider these conditions when prescribing Imegli 500mg Tablet and may adjust the dose or closely monitor patients with these health issues.

Contraindications

• Acute or Chronic Metabolic Acidosis
• Renal Failure and Impairment
• Cardiac Failure
• Insulin-Dependent Diabetes Mellitus (IDDM)
• Severe Impairment of Thyroid Function
• Acute or Chronic Alcoholism
• Conditions Causing Tissue Hypoxia
• Pregnancy and Lactation

Pregnancy & Lactation

Maintaining optimal blood glucose levels is crucial for pregnant individuals with diabetes to ensure the health of both the mother and the developing fetus.

• Uncontrolled Diabetes and Pregnancy: Uncontrolled diabetes during pregnancy, whether it's gestational diabetes (diabetes that develops during pregnancy) or pre-existing diabetes (such as Type 1 or Type 2 diabetes), can pose risks to the developing fetus. High blood glucose levels can increase the risk of congenital abnormalities (birth defects) and perinatal mortality (death around the time of birth).
• Insulin in Pregnancy: During pregnancy, the management of diabetes often involves a shift toward using insulin therapy rather than oral medications or other diabetes medications. Insulin is typically considered the safest and most effective option for controlling blood glucose levels during pregnancy. It allows for precise control of blood sugar levels, which is essential for reducing the risk of birth defects and other complications.
• Normalizing Blood Glucose Levels: The goal of diabetes management during pregnancy is to maintain blood glucose levels as close to normal as possible. Tight blood glucose control is associated with a lower risk of adverse outcomes for both the mother and the baby.
• Risk Reduction: By carefully managing blood glucose levels with insulin therapy and lifestyle modifications (including a balanced diet and regular physical activity), healthcare providers aim to reduce the risk of birth defects and other complications associated with uncontrolled diabetes during pregnancy.
• Collaborative Care: Pregnant individuals with diabetes should work closely with their healthcare team, which may include obstetricians, endocrinologists, diabetes educators, and dietitians. These professionals can provide guidance on insulin dosing, blood glucose monitoring, and lifestyle adjustments to support a healthy pregnancy.

Precautions & Warnings

• Imegli 500mg Tablet should be avoided if you are allergic to any of the medicines or the components in it.
• Before starting the treatment, inform your doctor about your medical history and the medications you take, including herbs and supplements.
• This can help prevent unwanted effects. Imegli 500mg Tablet is not recommended for use in patients with severe liver or kidney disease.
• It is unknown whether Imegli 500mg Tablet can be given to pregnant women or breastfeeding mothers.
• Hence, inform your doctor if you are pregnant or breastfeeding. It is not recommended for use in children below 18 years of age.

Storage Conditions

Store in a cool and dry place, below 30°C, secure from light.